Increasing antimalarial drug resistance in Uganda and revision of the national drug policy

被引:52
作者
Kamya, MR
Bakyaita, NN
Talisuna, AO
Were, WM
Staedke, SG
机构
[1] Makerere Univ, Dept Med, Sch Med, Kampala, Uganda
[2] Minist Hlth, Kampala, Uganda
[3] Rubaga Hosp, Kampala, Uganda
[4] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA
关键词
Plasmodium falciparum; malaria; drug resistance; drug policy; Uganda;
D O I
10.1046/j.1365-3156.2002.00974.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Chloroquine (CQ) resistance was first documented in Uganda in 1988. Subsequent surveillance of antimalarial drug resistance, conducted by the Ugandan Ministry of Health and several research organizations, suggests that resistance to CQ is now widespread, reaching critical levels in many areas of the country. In June 2000, the Ministry of Health held a National Consensus Meeting to evaluate the available drug efficacy data and review the national antimalarial drug policy. After extensive debate, the combination of CQ + sulfadoxine-pyrimethamine (SP) was chosen to replace CQ as the first-line treatment of uncomplicated malaria as an interim policy. This review evaluates the in vivo drug efficacy studies conducted in Uganda since 1988 and issues confronted in revision of the drug policy. The Ugandan experience illustrates the challenges faced by sub-Saharan African countries confronted with rising CQ resistance but limited data on potential alternative options. The choice of CQ + SP as a provisional policy in the absence of prerequisite efficacy, safety and cost-effectiveness data reflects the urgency of the malaria treatment problem, and growing pressure to adopt combination therapies. Surveillance of CQ + SP treatment efficacy, collection of additional data on alternative regimens and active consensus building among key partners in the malaria community will be necessary to develop a rational long-term antimalarial treatment policy in Uganda.
引用
收藏
页码:1031 / 1041
页数:11
相关论文
共 45 条
[1]  
[Anonymous], 1996, WHOMAL961077
[2]   A systematic approach to the development of a rational malaria treatment policy in Zambia [J].
Barat, LM ;
Himonga, B ;
Nkunika, S ;
Ettling, M ;
Ruebush, TK ;
Kapelwa, W ;
Bloland, PB .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1998, 3 (07) :535-542
[3]   CHLOROQUINE-RESISTANT PLASMODIUM-FALCIPARUM IN EASTERN SUDAN [J].
BAYOUMI, RA ;
BABIKER, HA ;
IBRAHIM, SM ;
GHALIB, HW ;
SAEED, BO ;
KHIDER, S ;
ELWASILA, M ;
KARIM, EA .
ACTA TROPICA, 1989, 46 (03) :157-165
[4]  
Bloland PB, 1999, ANN TROP MED PARASIT, V93, P5, DOI 10.1080/00034989958753
[5]   BEYOND CHLOROQUINE - IMPLICATIONS OF DRUG-RESISTANCE FOR EVALUATING MALARIA THERAPY EFFICACY AND TREATMENT POLICY IN AFRICA [J].
BLOLAND, PB ;
LACKRITZ, EM ;
KAZEMBE, PN ;
WERE, JBO ;
STEKETEE, R ;
CAMPBELL, CC .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (04) :932-937
[6]  
Bloland PB, 1998, TROP MED INT HEALTH, V3, P543
[7]  
BLOLAND PB, 2000, B WORLD HEALTH ORGAN, V78, P1374
[8]   CHLOROQUINE TREATMENT OF FALCIPARUM-MALARIA IN AN AREA OF KENYA OF INTERMEDIATE CHLOROQUINE RESISTANCE [J].
BRANDLINGBENNETT, AD ;
OLOO, AJ ;
WATKINS, WM ;
BORIGA, DA ;
KARIUKI, DM ;
COLLINS, WE .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1988, 82 (06) :833-837
[9]   Amodiaquine remains effective for treating uncomplicated malaria in West and Central Africa [J].
Brasseur, P ;
Guiguemde, R ;
Diallo, S ;
Guiyedi, V ;
Kombila, A ;
Ringwald, P ;
Olliaro, P .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1999, 93 (06) :645-650
[10]   CHALLENGES FACING ANTIMALARIAL THERAPY IN AFRICA [J].
CAMPBELL, CC .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1207-1211